Manipram 20 Mg 14 Tablets

Brand : werrick pharmaceuticals

Rs. 217.42

Rs. 228.90

|

QUICK DELIVERY

SPECIFICATION

Requires Prescription (YES/NO)

Yes

Generics

Citalopram HBr

Used For

Depression

How it works

The mechanism of action of citalopram HBr as an antidepressant is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). In vitro and in vivo studies in animals suggest that citalopram is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine (NE) and dopamine (DA) neuronal reuptake. Tolerance to the inhibition of 5-HT uptake is not induced by long-term (14-day) treatment of rats with citalopram. Citalopram is a racemic mixture (50/50), and the inhibition of 5-HT reuptake by citalopram is primarily due to the (S)-enantiomer.

USAGE AND SAFETY

Dosage

Citalopram HBr

Side Effects

GI upset , tremor , somnolence , dry mouth , anorexia , agitation , decreased lipid , anxiety , confusion , sleep disorders , tinnitus , yawning , pruritis , impotence , amnesia , apathy , increases salivation , increased sweating , abnormal accommodation. Hyponatraemia , bleeding disorders , serotonin syndrome .

Drug Interactions

MAOIs, lithium , tryptophan , pimozide , other neuroleptics , St.John's wort, other SSRIs , SNRIs , 5HT1 agonists , triptans , other serotonergic drugs , linezolid , drugs that prolong QT interval , tramadol , anticoagulants , NSAIDs and other drugs affecting plastelet function . CYP2D6 substrates (e.g., metoprolol) , CYP2C19 inhibitors (e.g. PPIs) , cimetidine , drugs that reduce seizure threshold . Drugs that induce hypokalaemia or hypomagnesaemia. Alcohol.

Indication

It is used in depressive disorders (endogenous and non-endogenous).

When not to Use

Hyersensitive to any of the ingredients.

PRECAUTIONS

Precaution

All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.

WARNINGS

Warning 1

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of this medicine or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need.

Warning 2

Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior.

Warning 3

Families and caregivers should be advised of the need for close observation and communication with the prescriber. It is not approved for use in pediatric patients.